Stacey Chang-Douglass
Head of Health Economics and Director in Consulting
Stacey is Head of Health Economics and Director in Consulting at Clarivate.
Stacey has nearly 15 years’ experience in health economics and outcome research at consultancies and at NICE. She specialises in economic modelling to support HTA submissions, global model development and country adaptation and national guidelines across an extensive range of therapeutic areas.
Prior to joining Clarivate, Stacey held senior positions at different consultancies, as Principal Consultant at Parexel, Director in Health Economics at Lumanity and Research Scientist at Evidera, where she led multidisciplinary projects for economic modelling and evidence synthesis. She provided quality assurance for deliverables and technical guidance for the internal team and provided strategic insights to ensure a long-term partnership with the clients.
Stacey serves as a standing committee member at the Medical Technologies Advisory Committee at NICE since 2022. Stacey also serves as a reviewer of funding proposals and HTA reports for NIHR in the UK since 2015.
Stacey holds an MSc in International Health Policy from London School of Economics and a PhD in Health Sciences from the University of York, which focused on outcome measurements in economic evaluations.
Latest news
LibTech Insights and Clarivate Announce “AI Essentials for Academic Libraries: Beyond the Basics”
Following the success of last year’s program, Clarivate and Choice team up once again to explore AI literacy topics in a three-part course June 25, 2026, Chicago, IL – Choice…
Clarivate and Healthcare Executive Unveil the 2026 Top 100 Most Innovative Chinese Pharmaceutical Companies
New ranking highlights the growing global influence of Mainland China’s pharmaceutical innovators London, U.K. June 25, 2026. Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, and Healthcare Executive,…
